H2020Докторантска мрежа2017–2020

PRINT-AID · Multidisciplinary European training network for development of personalized anti-infective medical devices combining printing technologies and antimicrobial functionality

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2017-01-01 → 2020-12-31
Финансиране от ЕС
2 265 900 €
Участници
13
Схема
MSCA-ITN-ETN

Линиите свързват координатора с партньорите.

Накратко на български

Медицински устройства, като катетри и импланти, се разработват чрез 3D принтиране, за да се борят с бактериалните биофилми. Това помага за намаляване на болничните инфекции, които годишно причиняват хиляди смъртни случаи и високи разходи в Европа.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Multidisciplinary European training network for development of personalized anti-infective medical devices combining printing technologies and antimicrobial functionality

The Print-Aid project successfully trained nine doctoral students in a multidisciplinary environment that involved 10 research institutions in Europe and 2 in the US with an aim to shorten the path from basic research to clinical applications in the field of medical devices and bio-fabrication. The project created a network of young professionals, with a profound, yet wide understanding of the field of infectious diseases associated with medical devices, and the tools/knowledge needed to concretize clinical developments. These included microbiological models, formulation science, data management as well as the industrial and regulatory outlook. The project also offered stakeholders and policymakers a strong proof-of-concept effort of innovative alternatives to reduce the burden (financial costs and mortality/morbidity) associated with hospital-acquired infections. According to the European Centre for Disease Prevention and Control - ECDC, more than 4 million EU patients acquire nosocomial infections every year, resulting in 37,000 deaths and costing about EUR 7 billion annually. At least half of all these infections is related to the use of medical devices, including catheters and medical implants, from which ca. 80% associate with microbial biofilms. To date, all licensed antibiotics have been developed against planktonic bacteria, and their efficacy against biofilms has usually not been determined. The Print-Aid project had following three specific aims: 1) To educate doctoral students in the development of next-generation anti-infective medical devices by (i) applying state-of-the-art fabrication and drug delivery technologies (3D-printing) and to (ii) explore if they are beneficial (from both the fabrication and the functional perspectives) in protecting against biofilm-related infections. 2) To learn how to set up a collection of anti-biofilm compounds and to develop novel anti-biofilm formulations. 3) To provide the doctoral students with an insight in building a generic research toolbox for developing novel anti-biofilm agents, including in vitro/vivo models for evaluating the efficacy of anti-biofilm compounds, tools for data integration and standardization. The close research collaboration, combined with a tailored training program with on-line courses, workshops, summer schools and outreach activities, provided a framework for personalized medicine with the main focus on improving antimicrobial formulations to enhance the functionality of the medical device(s) using printing technologies.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

According to ECDC, over 4 million healthcare-associated infections in the EU cause 37,000 deaths and cost EUR 7 billion/year. Half of them are related to medical devices (i.e., catheters, implants) and 80% of these are related to bacterial biofilms. A recent EC report highlighted the medical device sector’s role in driving EU economic growth, employing 500k people in 25k companies (80% are SMEs) with annual sales of EUR 85 billion. The strategy to prevent medical device-infections is alteration of the device’s surface with antimicrobials. However, current antimicrobial surfaces don’t control bacterial growth in tissue surrounding implants, and only Sterilex® has received regulatory approval in the US as anti-biofilm agent. Participants in this proposal have earlier demonstrated a dramatic in vitro inhibition of biofilm formation by 3D-printing surfaces with antibiotics incorporated into the carrier polymers. This discovery opens new possibilities for printed medical devices that better resist biofilms. Our objective is to set-up a new European education platform to guide and inspire young researchers in the intersectoral exploration of innovative routes to counteract microbial biofilms by fabricating anti-infective, tailored, 3D-printed medical devices. Current opportunities for young researchers to receive an structured, inter-sectoral and up-to-date education on personalized medicine and medical devices are marginal, and to our knowledge PRINT-AID is the first ETN set up for this purpose. State-of-the-art printing technologies will be combined with in vitro and in vivo biofilm models and novel tools for data integration/standardization. Doctoral training will be performed within a high-quality network of 12 participants (5 industrial) from the EU and US. It will include online and face-to-face courses taught by researchers with academic and industrial expertise in biofilms, 3D-printing research, antimicrobials, material science, and drug development.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз